Title |
Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease
|
---|---|
Published in |
Arthritis Research & Therapy, June 2001
|
DOI | 10.1186/ar318 |
Pubmed ID | |
Authors |
Andrew D Cook, Emma L Braine, Ian K Campbell, Melissa J Rich, John A Hamilton |
Abstract |
There is mounting evidence for a role of the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory disease, including arthritis. In the present study, we examined the effectiveness of treatment of collagen-induced arthritis (CIA) with a neutralizing mAb to GM-CSF. DBA/1 mice were immunized for the development of CIA and treated at different times, and with different doses, with neutralizing mAb to GM-CSF or isotype control mAb. Anti-GM-CSF mAb treatment prior to the onset of arthritis, at the time of antigen challenge, was effective at ameliorating the ensuing disease. Modulation of arthritis was seen predominantly as a reduction in overall disease severity, both in terms of the number of limbs affected per mouse and the clinical score of affected limbs. Importantly, anti-GM-CSF mAb treatment ameliorated existing disease, seen both as a reduction in the number of initially affected limbs progressing and lower numbers of additional limbs becoming affected. By histology, both inflammation and cartilage destruction were reduced in anti-GM-CSF-treated mice, and the levels of tumor necrosis factor-a and IL-1beta were also reduced in joint tissue washouts of these mice. Neither humoral nor cellular immunity to type II collagen, however, was affected by anti-GM-CSF mAb treatment. These results suggest that the major effect of GM-CSF in CIA is on mediating the effector phase of the inflammatory reaction to type II collagen. The results also highlight the essential role of GM-CSF in the ongoing development of inflammation and arthritis in CIA, with possible therapeutic implications for rheumatoid arthritis. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Spain | 1 | 1% |
Unknown | 80 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 19 | 23% |
Researcher | 11 | 13% |
Student > Master | 8 | 10% |
Student > Doctoral Student | 5 | 6% |
Professor | 4 | 5% |
Other | 19 | 23% |
Unknown | 16 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 22% |
Agricultural and Biological Sciences | 18 | 22% |
Immunology and Microbiology | 14 | 17% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Other | 7 | 9% |
Unknown | 18 | 22% |